Vladimir Cmiljanović

发表

Targeting phosphoinositide 3-kinase: moving towards therapy.

Bernd Giese, B. Giese, M. Wymann, 2008, Biochimica et biophysica acta.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

D. Fabbro, L. Cascione, D. Rossi, 2017, Clinical Cancer Research.

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

D. Fabbro, L. Cascione, A. Stathis, 2019, Cancers.

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

D. Fabbro, M. Zvelebil, Roger L. Williams, 2017, Nature Communications.

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

J. Mestan, D. Fabbro, M. Zvelebil, 2017, Journal of medicinal chemistry.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

R. Herrmann, H. Hawle, S. Dimitrijević, 2018, European journal of cancer.

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

C. Schnell, C. García-echeverría, B. Giese, 2009, Molecular Cancer Research.

Targeting lipid signalling in cancer

Vladimir Cmiljanović, 2010 .

Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamsters

T. Klimkait, M. Beer, Vladimir Cmiljanović, 2023, bioRxiv.

Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation

L. Cascione, R. Giugno, Vladimir Cmiljanović, 2021, Non-coding RNA.

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

D. Fabbro, L. Cascione, A. Stathis, 2019, Cancers.

Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition

D. Fabbro, M. Zvelebil, Roger L. Williams, 2015 .

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

C. Schnell, C. García-echeverría, B. Giese, 2009, Molecular Cancer Research.

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

F. Janku, M. Opyrchal, A. Adjei, 2024, Cancers.

A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.

Vladimir Cmiljanović, Jenna N. Kelly, P. V’kovski, 2024, Nature microbiology.